Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ulrike Gruber-Mösenbacher"'
Autor:
Ulrike Gruber-Mösenbacher, Lauren Katzell, Mark McNeely, Elisabeth Neier, Bobo Jean, Avelino Kuran, Srikar Chamala
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1380-1389 (2021)
PURPOSECancer is becoming increasingly prevalent among the group of treatable diseases in African countries. There is a shortage of clinicians and pathologists available for cancer diagnosis and treatment. These limited resources must be efficiently
Externí odkaz:
https://doaj.org/article/b92fe2d067b34c15889aad5845a44ead
Autor:
Bobo Jean, Srikar Chamala, Elisabeth Neier, Lauren Katzell, Avelino Kuran, Ulrike Gruber-Mösenbacher, Mark McNeely
Publikováno v:
JCO Global Oncology
PURPOSE Cancer is becoming increasingly prevalent among the group of treatable diseases in African countries. There is a shortage of clinicians and pathologists available for cancer diagnosis and treatment. These limited resources must be efficiently
Autor:
Richard Wasicky, Markus Rauter, Katja Schmitz, Gerald Webersinke, Josef Eckmayr, Ulrike Setinek, Dagmar Krenbek, Bernd Lamprecht, Georg Hutarew, Rainer Kolb, Gudrun Absenger, Helmut Popper, Tamara Hernler, Peter Errhalt, Ulrike Gruber-Mösenbacher, Maximilian Hochmair, Luka Brcic, Leonhard Müllauer, Robert Pirker, Georg Pall, Wolfgang Hilbe
Publikováno v:
memo - Magazine of European Medical Oncology. 13:11-26
The knowledge on molecular alterations in lung cancer have increased during the last decade considerably. Almost every year new genes were detected being targetable, and drugs have been developed and provided for those patients being diagnosed with s
Autor:
Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Hutarew, Maximilian Hochmair, Gudrun Absenger, Luka Brcic, Leonhard Müllauer, Gerhard Dekan, Ulrike Setinek, Dagmar Krenbek, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Rainer Kolb, Gerald Webersinke, Tamara Hernler, Georg Pall, Sigurd Lax, Andrea Mohn-Staudner
Publikováno v:
memo - Magazine of European Medical Oncology. 9:191-200
Autor:
Richard L. Attanoos, Marie Christine Aubry, Roberto J. Barrios, Mary Beth Beasley, Jennifer Brainard, Elisabeth Brambilla, Kelly J. Butnor, Lucian R. Chirieac, Carlyne D. Cool, Gail Deutsch, Megan K. Dishop, Carol F. Farver, Douglas B. Flieder, William K. Funkhouser, Anthony A. Gal, Allen R. Gibbs, Linda K. Green, Ulrike Gruber-Mösenbacher, Donald G. Guinee, Abida K. Haque, Robert Homer, Aliya N. Husain, Diana N. Ionescu, Marina Ivanovic, Jaishree Jagirdar, M. Kelly Keating, Keith M. Kerr, Alyssa Kraynie, Sylvie Lantuejoul, Kevin O. Leslie, Leslie A. Litzky, Haresh Mani, Andre L. Moreira, Bruno Murer, Ronald C. Neafie, Helmut H. Popper, Gary W. Procop, Negar Rassaei, Maxwell L. Smith, Thomas A. Sporn, William D. Travis, David H. Walker, Frances V. White, Joanne L. Wright, Sherif R. Zaki, Dani S. Zander
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4c20cdb14b0cfa05f777a76f34c063d
https://doi.org/10.1016/b978-0-323-39308-9.01002-5
https://doi.org/10.1016/b978-0-323-39308-9.01002-5
Autor:
Michael Studnicka, Helmut Popper, Robert Pirker, Fritz Wrba, Wolfgang Hulla, Wolfgang Hilbe, Ulrike Gruber-Mösenbacher, Ferdinand Ploner, Andrea Mohn-Staudner
Publikováno v:
memo - Magazine of European Medical Oncology. 4:248-253
Patients with stage IIIB and IV non-small-cell lung carcinoma (NSCLC) harbouring activating mutations of the epidermal growth factor receptor (EGFR) gene should be treated first-line with gefitinib or erlotinib, EGFR tyrosine kinase inhibitors (TKI).
Autor:
Helmut Popper, Ferdinand Ploner, Andrea Mohn-Staudner, Wolfgang Hilbe, Fritz Wrba, Ulrike Gruber-Mösenbacher, Michael Studnicka, Robert Pirker, Wolfgang Hulla, und die Arbeitsgruppe Pulmopathologie der Ögp-Iap
Publikováno v:
Wiener klinische Wochenschrift. 123:316-321
Patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) harboring an activating mutation of the Epidermal Growth Factor Receptor (EGFR) Gene should be treated first-line with Gefitinib, an EGFR tyrosine kinase inhibitor (TKI). EGF recep
Autor:
Reinhard Motz, Michael Scarpatetti, Wolfgang Stiglbauer, Hans-Christian Bankl, Johann Feichtinger, Andreas Kiefer, Monika Hackl, Roland Sedivy, Ulrike Gruber-Mösenbacher, Johannes A. Hainfellner, Thomas Waldhör, Harald Heinzl, Karl Rössler, Angelika Reiner-Concin, Hans Maier, Bernd Richling, Carmen Idriceanu, Adelheid Wöhrer, Matthias Preusser
Publikováno v:
Journal of Neuro-Oncology. 95:401-411
In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported. The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for
Publikováno v:
Wiener klinische Wochenschrift. 117:610-614
Mesenteric inflammatory veno-occlusive disease (MIVOD) is a relatively recently known and not very often diagnosed form of ischemic bowel disease of low incidence und unknown etiology. We present the case of a patient who after presentation of inconc
Autor:
Helmut, Popper, Fritz, Wrba, Ulrike, Gruber-Mösenbacher, Wolfgang, Hulla, Robert, Pirker, Wolfgang, Hilbe, Michael, Studnicka, Andrea, Mohn-Staudner, Ferdinand, Ploner, Bettina, Zelger
Publikováno v:
Wiener klinische Wochenschrift. 123(9-10)
Patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) harboring an activating mutation of the Epidermal Growth Factor Receptor (EGFR) Gene should be treated first-line with Gefitinib, an EGFR tyrosine kinase inhibitor (TKI). EGF recep